Immunomic Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.immunomix.com
Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Immunomic Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05698199
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Immunomic Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05422781
- Locations
- 🇺🇸
University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States
A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device
Phase 1
Completed
- Conditions
- Allergic Rhinitis
- Interventions
- Biological: CryJ2-DNA-LAMP plasmid vaccine by intradermal injectionOther: Saline Control
- First Posted Date
- 2014-05-26
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Immunomic Therapeutics, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02146781
- Locations
- 🇺🇸
East West Medical Research Institute, Honolulu, Hawaii, United States
A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects
Phase 1
Completed
- Conditions
- Allergic Rhinoconjunctivitis
- Interventions
- Biological: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- Immunomic Therapeutics, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT01966224
- Locations
- 🇺🇸
East West Medical Research Institute, Honolulu, Hawaii, United States
A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid
Phase 1
Completed
- Conditions
- Allergic Rhinoconjunctivitis
- Interventions
- Biological: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- Immunomic Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01707069
- Locations
- 🇺🇸
East West Medical Research Institute, Honolulu, Hawaii, United States